Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD) today and set a price target of $14. The company’s shares opened today at $5.60.
“Updates from recent presentations strengthen the case for TXMD’s leading women’s health portfolio. We’re encouraged by several important metrics, including: 1) Imvexxy average daily script volume grew 11% (month/month) in Feb. to continue on a best-in- class trajectory. 2) Based on Jan-Feb (excl. March), Imvexxy still outpaces the most recent competitive launch from a quarterly perspective. 3) Reimbursement progress is being made, with Imvexxy now adjudicated at major plans covering ~49% of commercial lives. 4) New clinical data shows Bijuva improves vaginal dryness during intercourse in women ≥55 years old. 5) In a Ph3 clinical trial—Annovera did not have a negative impact on sexual function or activity. We look forward to additional updates from TXMD at our 29th Annual HC Conference (3/19). Reiterate Outperform, details inside.”
According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -3.0% and a 42.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on TherapeuticsMD is a Moderate Buy with an average price target of $20.50, a 266.1% upside from current levels. In a report issued on March 12, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $39.39 million. In comparison, last year the company had a GAAP net loss of $21.43 million.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD: